Ono Pharmaceutical is to develop Relistor® (methylnaltrexone bromide) for the Japanese market, following a licensing deal with Progenics Pharmaceuticals. The recently launched product is the first medicine approved for the treatment of opioid-induced constipation in advanced illness patients, and has been co-developed with Wyeth.